Yue Zhao

Dr. Yue Zhao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2016 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
RZRui Zheng
Rui Zheng
QZQian Zhang
Qian Zhang
YGYidan Guo
Yidan Guo
YFYue Feng
Yue Feng
LLLi Liu
Li Liu
XXXueshan Xia
Xueshan Xia
In the past decade, the carbapenemase-producing Enterobacteriaceae (CPE) have been reported worldwide. Emergence of carbapenemase-producing strains among Enterobacteriaceae has been a challenge for treatment of clinical infection. The present study was undertaken to investigate the characteristics of carbapenem-resistant Klebsiella pneumoniae recovered from an outbreak that affected 17 neonatal patients in neonatal intensive care unit (NICU) of Kunming City Maternal and Child health Hospital, which is located in the Kunming city in far southwest of China. Minimum inhibitory concentrations (MICs) for antimicrobial agents were determined according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI); Modified Hodge test and Carba-NP test were preformed to identified the phenotypes of carbapenemases producing; To determine whether carbapenem resistance was transferable, a conjugation experiment was carried out in mixed broth cultures; Resistant genes were detected by using PCR and sequencing; Plasmids were typed by PCR-based replicon typing method; Clone relationships were analyzed by using multilocus-sequence typing (MLST) and pulsed field gel electrophoresis (PFGE). Eighteen highly carbapenem-resistant Klebsiella pneumoniae were isolated from patients in NICU and one carbapenem-resistant K. pneumoniae isolate was detected in incubator water. All these isolates harbored bla NDM-1. Moreover, other resistance genes, viz., bla IMP-4 , bla SHV-1 , bla TEM-1 , bla CTX-M-15 , qnrS1, qnrB4, and aacA4 were detected. The bla NDM-1 gene was located on a ca. 50 kb IncFI type plasmid. PFGE analysis showed that NDM-1-producing K. pneumoniae were clonally related and MLST assigned them to sequence type 105. NDM-1 producing strains present in the hospital environment pose a potential risk and the incubator water may act as a diffusion reservoir of NDM-1- producing bacteria. Nosocomial surveillance system should play a more important role in the infection control to limit the spread of these pathogens.

15 February 2017 in Viruses
Verified
Journal Article
Open access
PDF file
ZMZhijiang Miao
Zhijiang Miao
LGLi Gao
Li Gao
YSYindi Song
Yindi Song
MYMing Yang
Ming Yang
MZMi Zhang
Mi Zhang
XXXueshan Xia
Xueshan Xia
Human Pegivirus-1 (HPgV-1) may have a beneficial impact on disease progression in human immunodeficiency virus-1 (HIV-1) infection. However, analysis of the genotypic diversity of HPgV-1 and its relevance to the progression of HIV-1 disease remains limited. A total of 1062 HIV-1-infected individuals were recruited in all sixteen prefectures of Yunnan province, China. The reverse transcription nested polymerase chain reaction (RT-nPCR), phylogenetic analyses, and clinical data analyses were used to detect HPgV-1 infection, determine genotype, and analyze HPgV-1 genotype impact on HIV-1 disease progression. The overall positive rate of HPgV-1 RNA was 23.4% (248/1062), and the frequency of HPgV-1 infection in injecting drug users (IDUs) (28.5%, 131/460) was significantly higher than in heterosexuals (19.4%, 117/602). Multiple genotypes were identified in 212 subjects with successful sequencing for the E2 gene, including genotype 7 (55.7%), genotype 3 (34.9%), genotype 4 (4.7%), genotype 2 (3.3%), and an unclassified group (1.4%). Moreover, genotype 7 predominated in IDUs, whereas genotype 3 was the most common in heterosexuals. Our results revealed that HPgV-1 genotype 7 groups exhibited significantly lower HIV-1 viral load and higher CD4+ cell counts. This finding suggests that HPgV-1 genotype 7 may be associated with a better progression of HIV-1 disease.

30 July 2025 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
ZWZhi-Wei Wang
Zhi-Wei Wang
XWXiao-Jian Wu
Xiao-Jian Wu
QDQian-Long Dai
Qian-Long Dai
ZLZhen-Lin Liu
Zhen-Lin Liu
CZCheng-Gang Zhao
Cheng-Gang Zhao
WXWang Xiaobo
Wang Xiaobo

21 February 2026 in Biochemical Pharmacology
Verified
Journal Article
Closed access
XYXin Yang
Xin Yang
HCHang Chen
Hang Chen
TWTing Wu
Ting Wu
ZJZheng-Yang Ji
Zheng-Yang Ji
ZWZhi-Wei Wang
Zhi-Wei Wang
XWXiaobo Wang
Xiaobo Wang

20 November 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
XYXin Yang
Xin Yang
ZWZhi-Wei Wang
Zhi-Wei Wang
ZLZhen-Lin Liu
Zhen-Lin Liu
CCCui Chen
Cui Chen
ZJZheng-Yang Ji
Zheng-Yang Ji
MZMin Zhou
Min Zhou